GB1520200A - Antitumour vaccines and their preparation - Google Patents
Antitumour vaccines and their preparationInfo
- Publication number
- GB1520200A GB1520200A GB53723/76A GB5372376A GB1520200A GB 1520200 A GB1520200 A GB 1520200A GB 53723/76 A GB53723/76 A GB 53723/76A GB 5372376 A GB5372376 A GB 5372376A GB 1520200 A GB1520200 A GB 1520200A
- Authority
- GB
- United Kingdom
- Prior art keywords
- species
- virus
- mammal
- oncolysate
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229940022399 cancer vaccine Drugs 0.000 title 1
- 241000894007 species Species 0.000 abstract 4
- 241000124008 Mammalia Species 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 238000004113 cell culture Methods 0.000 abstract 2
- 238000003306 harvesting Methods 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 241000700618 Vaccinia virus Species 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 230000008014 freezing Effects 0.000 abstract 1
- 238000007710 freezing Methods 0.000 abstract 1
- 230000008076 immune mechanism Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 239000008188 pellet Substances 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 238000010257 thawing Methods 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/691,486 US4108983A (en) | 1976-06-01 | 1976-06-01 | Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1520200A true GB1520200A (en) | 1978-08-02 |
Family
ID=24776726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB53723/76A Expired GB1520200A (en) | 1976-06-01 | 1976-12-23 | Antitumour vaccines and their preparation |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US4108983A (https=) |
| JP (1) | JPS52148617A (https=) |
| AU (1) | AU511071B2 (https=) |
| CA (1) | CA1073814A (https=) |
| DE (1) | DE2705610A1 (https=) |
| FR (1) | FR2353641A1 (https=) |
| GB (1) | GB1520200A (https=) |
| NZ (1) | NZ182891A (https=) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0037441B1 (en) * | 1980-03-10 | 1984-05-09 | Seiji Arakawa | Pharmaceutical compositions useful as cellular immunopotentiator and anti-tumor agent, process for production thereof and microorganism used therein |
| JPS5835121A (ja) * | 1981-08-20 | 1983-03-01 | ビラス・ヴィー・リクハイト | 免疫刺激性補助剤からなる抗原及び免疫療法におけるその使用 |
| US4652522A (en) * | 1983-07-05 | 1987-03-24 | The University Of Pennsylvania | Continuous lymphocyte cell lines, their production and use |
| JPS6038328A (ja) * | 1983-08-11 | 1985-02-27 | Handai Biseibutsubiyou Kenkyukai | 抗腫瘍免疫誘導の増強法 |
| US6338853B1 (en) | 1987-04-23 | 2002-01-15 | Jean-Claude Bystryn | Anti-cancer vaccine |
| US5030621A (en) * | 1987-04-23 | 1991-07-09 | Bystryn Jean Claude | Shed melanoma antigen compositions |
| US5124148A (en) * | 1988-04-27 | 1992-06-23 | United Cancer Research Institute | Method for treating viral diseases with attenuated virus |
| US5215745A (en) * | 1988-04-27 | 1993-06-01 | United Cancer Research Institute | Method for treating viral diseases with attenuated virus |
| WO1990011765A1 (en) * | 1989-04-11 | 1990-10-18 | Board Of Regents, The University Of Texas System | Antitumor preparation obtained following oncolysate treatment |
| US5290551A (en) * | 1990-05-08 | 1994-03-01 | Thomas Jefferson University | Treatment of melanoma with a vaccine comprising irradiated autologous melanoma tumor cells conjugated to a hapten |
| US7585512B1 (en) | 1990-05-08 | 2009-09-08 | Thomas Jefferson University | Composition and method of using tumor cells |
| CA2161671A1 (en) | 1993-04-30 | 1994-11-10 | Robert M. Lorence | Methods of treating and detecting cancer using viruses |
| US6051227A (en) * | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6136307A (en) * | 1997-08-13 | 2000-10-24 | Oncolytics Biotech Inc. | Reovirus for the treatment of cellular proliferative disorders |
| US6565831B1 (en) * | 1999-02-24 | 2003-05-20 | Oncolytics Biotech Inc. | Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| US6110461A (en) * | 1997-08-13 | 2000-08-29 | Oncolytics Biotech Inc. | Reovirus for the treatment of neoplasia |
| US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| US7780962B2 (en) * | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
| IL145899A0 (en) * | 1999-04-15 | 2002-07-25 | Pro Virus Inc | Treatment of neoplasms with viruses |
| US6586411B1 (en) | 2000-08-16 | 2003-07-01 | Mayo Foundation For Medical Education And Research | System for monitoring the location of transgenes |
| US6896881B1 (en) * | 1999-09-24 | 2005-05-24 | Mayo Foundation For Medical Education And Research | Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family |
| US7015205B1 (en) | 1999-10-18 | 2006-03-21 | St. Vincent's Hospital And Medical Center Of New York | Melanoma vaccine and methods of making and using same |
| US7118740B1 (en) | 2000-09-22 | 2006-10-10 | Mayo Foundation For Medical Education And Research | Method for limiting the growth of cancer cells using an attenuated measles virus |
| ES2551306T3 (es) * | 2006-02-13 | 2015-11-17 | Oncolytics Biotech Inc. | Uso de inmunosupresión local de baja dosis para potenciar una terapia viral oncolítica |
| US9951117B2 (en) | 2010-09-02 | 2018-04-24 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
| WO2012031137A2 (en) | 2010-09-02 | 2012-03-08 | Mayo Foundation For Medical Education And Research | Vesicular stomatitis viruses |
| US9623096B2 (en) | 2011-11-09 | 2017-04-18 | Celverum Inc. | Virally infected hematopoietic cells and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3553312A (en) * | 1968-02-26 | 1971-01-05 | Flow Lab | Process for producing rubella-virus hemagglutinating antigen |
-
1976
- 1976-06-01 US US05/691,486 patent/US4108983A/en not_active Expired - Lifetime
- 1976-12-15 NZ NZ182891A patent/NZ182891A/xx unknown
- 1976-12-23 GB GB53723/76A patent/GB1520200A/en not_active Expired
-
1977
- 1977-01-05 CA CA269,176A patent/CA1073814A/en not_active Expired
- 1977-01-27 AU AU21735/77A patent/AU511071B2/en not_active Expired
- 1977-02-10 DE DE19772705610 patent/DE2705610A1/de active Granted
- 1977-05-31 FR FR7716547A patent/FR2353641A1/fr active Granted
- 1977-05-31 JP JP6391677A patent/JPS52148617A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPS52148617A (en) | 1977-12-10 |
| FR2353641A1 (fr) | 1977-12-30 |
| AU511071B2 (en) | 1980-07-24 |
| AU2173577A (en) | 1978-08-03 |
| US4108983A (en) | 1978-08-22 |
| CA1073814A (en) | 1980-03-18 |
| DE2705610A1 (de) | 1977-12-15 |
| DE2705610C2 (https=) | 1989-08-03 |
| FR2353641B1 (https=) | 1980-07-18 |
| NZ182891A (en) | 1984-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1520200A (en) | Antitumour vaccines and their preparation | |
| Heppner | Studies on serum‐mediated inhibition of cellular immunity to spontaneous mouse mammary tumors | |
| NO912642L (no) | Fremstilling av proteiner ved bruk av homolog rekombinasjon. | |
| TR199800607T1 (xx) | Dendritik h�cre uyar�c� fakt�r�. | |
| US3674864A (en) | Process for stabilizing preparations of interfering viruses | |
| GB2079786B (en) | Production of viral antigens | |
| Brunner et al. | Antigenic specificity of the cytolytic T lymphocyte (CTL) response to murine sarcoma virus-induced tumors. II. Analysis of the clonal progeny of CTL precursors stimulated in vitro with syngeneic tumor cells. | |
| Rabinowitz et al. | The formation of variants with a reversion of properties of transformed cells: I. Variants from polyoma-transformed cells grown in vivo | |
| ES336810A1 (es) | Un metodo para producir una cepa de celulas. | |
| Hirst et al. | A new method for concentrating influenza virus from allantoic fluid | |
| Müllbacher et al. | An improved colorimetric assay for T cell cytotoxicity in vitro | |
| GB1486186A (en) | Vaccines against feline leukaemia and the group of diseases associated with feline leukaemis/virus infection | |
| Blackman et al. | The effect of interferon treatment of targets on susceptibility to cytotoxic T-lymphocyte killing: augmentation of allogeneic killing and virus-specific killing relative to viral antigen expression | |
| Sato et al. | Effects of intradermal administration of streptococcal preparation OK-432 on interferon and natural killer cell activities in patients with oral cancer | |
| Takemoto et al. | Influence of acid polysaccharides on plaque formation by influenza A2 and B viruses | |
| Damjanov et al. | Embryo-derived teratocarcinomas elicit splenomegaly in syngeneic host | |
| SHIMOJO et al. | The nature of tumor antigen of adenovirus type 12 and its formation in cultured cells after infection | |
| US3418210A (en) | Hamster ascites tumor cell line bhk 21/c.13/t.6/ascites useful in submerged serum-free agar cultures to support virus growth | |
| CN106978397A (zh) | 一种人dc-cik免疫活性细胞及其制备方法 | |
| ATE86308T1 (de) | Menschlicher b-lymphotroper virus (hblv), isolierung und erzeugnisse. | |
| GB1135987A (en) | Attenuated live rubella virus vaccine and method of production | |
| GB1453035A (en) | Virus vaccine production | |
| Clark et al. | Sv40‐induced transformation of cells of the lizard Gekko gecko | |
| GB1481650A (en) | Chemical processes and products | |
| Abramoff et al. | Cytotoxicity of heterologous immune chicken serum to normal and neoplastic mouse tissues in culture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PS | Patent sealed [section 19, patents act 1949] | ||
| PCNP | Patent ceased through non-payment of renewal fee |